Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Next Previous
Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 655064 (Primary)
  • Indications Idiopathic thrombocytopenic purpura; Lupus nephritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 13 Oct 2020 Prof. In-Jin Jang is the principal investigator as per the results published in in the British Journal of Clinical Pharmacology
    • 13 Oct 2020 Results published in the British Journal of Clinical Pharmacology
    • 19 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top